Provention Bio to Present at the Virtual H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) is set to present at the virtual H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The management will deliver a pre-recorded fireside chat, accessible starting January 10 at 7:00 am E.T. Participants can view the presentation on the company's website, where it will be archived for 30 days. Provention Bio specializes in developing therapies to intercept and prevent immune-mediated diseases, with a pipeline that includes candidates for autoimmune conditions like type 1 diabetes and lupus.

RED BANK, N.J., Jan. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will present at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.

A replay of the pre-recorded fireside chat will be available beginning Monday, January 10, at 7:00 am E.T. and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. The webcast will be archived on the Company's website for 30 days following the presentation.  A copy of the presentation will also be posted on the company's corporate website in the investor's section.

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contacts:

Robert Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235

Sam Martin, Argot Partners
proventionbio@argotpartners.com
212-600-1902

Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808

View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-virtual-hc-wainwright-bioconnect-conference-301455154.html

SOURCE Provention Bio, Inc.

FAQ

When is Provention Bio presenting at the H.C. Wainwright BioConnect 2022 Conference?

Provention Bio will present at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022.

What time can I access the Provention Bio presentation at the conference?

The presentation will be accessible starting January 10, 2022, at 7:00 am E.T.

Where can I find the Provention Bio conference presentation?

The presentation can be found in the Events and Webcasts section of Provention Bio’s website.

How long will the Provention Bio presentation be available online?

The presentation will be archived on Provention Bio’s website for 30 days after the conference.

What is the focus of Provention Bio’s drug development?

Provention Bio focuses on developing therapies to intercept and prevent immune-mediated diseases, including conditions like type 1 diabetes and lupus.